基于Brighton标准的西班牙三个VAC4EU数据源中吉兰-巴雷综合征病例识别验证
共识别180例GBS病例,LOC1-2的PPV从4.8%(SIDIAP)到90%(VHUH)不等;将LOC4视为真病例时PPV升高。获取医院病历对实现高诊断确定性至关重要。
要点
- GBS诊断编码的PPV在不同数据源间差异显著,需结合数据源类型解读。
- 将LOC4纳入真病例后PPV升高,提示验证标准影响结果。
- 药物流行病学研究中使用医疗记录验证GBS病例十分必要。
核心结论
- 获取医院病历是实现GBS高诊断确定性的关键。
- 将LOC4视为真病例时PPV升高。
- 风险窗口时机和监管警报的影响不一致。
- PPV差异源于数据源类型和诊断信息来源的可及性。
研究设计与样本
- 使用ICD-10-CM编码识别病例,并采用Brighton协作组标准验证确定度(LOC1至LOC5)。
- 计算PPV并按风险窗口(接种后42天内/外)和监管警报前后分层。
主要发现
- 共识别180例GBS病例,大多数验证病例分类为LOC4(n=78),VHUH除外。
- LOC1-2(n=40)的PPV从4.8%(SIDIAP)到90%(VHUH)不等。
- 监管警报后PPV变化较小,置信区间基本不变。
- 风险窗口分析显示VID在窗口外PPV更高(36.4% vs 73.9%)。
- 将LOC1-4视为真病例时,PPV升高至65%(SIDIAP)和77.8%(VID)。
关键数值与推荐
- Brighton协作组标准确定度分级:LOC1(确定病例)至LOC4(证据不足),LOC5(非病例)。
- LOC1-2的PPV范围:4.8%(SIDIAP)至90%(VHUH)。
- 将LOC1-4作为真病例时PPV:65%(SIDIAP)和77.8%(VID)。
- VID风险窗口外PPV 73.9%,窗口内36.4%。
临床怎么用
- 在药物流行病学研究中使用多源真实世界数据识别GBS时,应进行病例验证。
- 获取医院病历可提高GBS诊断确定性,建议在数据可及情况下优先使用。
- 解读GBS诊断编码PPV时需考虑数据源类型和验证标准的影响。
局限性
- 不同数据源间PPV差异大,可能限制结果外推。
- 监管警报和风险窗口对PPV的影响不一致,需谨慎解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In July 2021, the European Medicines Agency issued a warning about reports of Guillain-Barré syndrome (GBS) following COVID-19 vaccination. As part of the Global COVID Vaccine Safety (GCoVS) project, we aimed to estimate the Positive Predictive Value (PPV) of GBS diagnostic codes across multiple sources to explore differential misclassification. METHODS: We extracted GBS cases who received COVID-19 vaccination from three European data sources (VID, SIDIAP, VHUH in Spain) occurring between 1st December 2020 and 30th November 2022, using ICD-10-CM codes. Cases were validated using the Brighton Collaboration criteria to establish level of certainty (LOC) ranging from LOC1 (definite case) to LOC4 (insufficient evidence to meet case definition), and LOC5 (non-case). PPV was calculated and results stratified by risk window (within or outside 42 days post-vaccination) and before or after the regulatory alert. RESULTS: Overall, 180 GBS cases were identified. Most validated cases were classified with LOC4 (n = 78), except in VHUH. PPVs for LOC1-2 (n = 40) varied from 4.8% (SIDIAP) to 90% (VHUH). The PPV shows small changes after the alert, but these shifts are minor, and the confidence intervals stay essentially the same. Risk-window analyses showed higher PPVs outside the risk window for VID (36.4% vs 73.9%). When using LOC1-4 as true cases, PPVs increased to 65% (SIDIAP) and 77.8% (VID), and stratified results varied. CONCLUSIONS: Access to in-hospital medical records was key to achieving high diagnostic certainty for GBS. PPVs increased when LOC4 were considered true cases. The impact of risk window timing and regulatory alerts was inconsistent. Differences in PPVs stem from data source type and access to information from the setting where the diagnosis is made. Our findings emphasise the importance of GBS cases' validation when conducting pharmacoepidemiological studies using medical charts to identify GBS cases across multiple real-world healthcare data sources.
引用
- Sabaté M, Riera-Arnau J, Ballarín E, et al. Validation of Guillain-Barré syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria. Vaccine. 2026. PMID: 41806493. doi:10.1016/j.vaccine.2026.128397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。